Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for BMY, sign up here.
Income Statement
Revenue
$45.0bn
Gross Profit
$34.3bn
Earning before Tax
$8.4bn
Net Income
$8.0bn
Net Income Common Shareholders
$8.0bn
EPS
3.88
Balance Sheet
Cash
$11.5bn
Debt
$39.8bn
Assets
$95.2bn
Liabilities
$65.7bn
Equity
$29.4bn
Enterprise Value
$134.5bn
Cash Flow Statement
Net Cash from Operations
$13.9bn
Net Cash from Investing
$-2.3bn
Net Cash from Financing
$-9.4bn
Net Cash Flow
$2.2bn
Free Cash Flow
$12.7bn
Free Cash Flow per Share
$6.22
Metrics
Price to Equity
13.01
Price to Equity (Damodaran)
13.22
Price to Book
3.55
Net Margin
0.18
Return on Equity
0.26
Return on Sales
0.19
Get immediate access to 5-years of reference grade data for BMY for free.
Sign upBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company''s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York.
Company Info
Industry
Drug Manufacturers - General
Employees
34,100
Address
Route 206 & Province Line Road
Princeton, NY 08543
United States
Phone
609 252 4621
Website
Last Updated
2024-02-16
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.